BLTE

Belite BioD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$200.00

+46.4% vs current

Most likely

Base case

60%

Probability

Target price

$165.29

+21.0% vs current

B-

Bear case

15%

Probability

Target price

$85.00

-37.8% vs current

AI sentiment snapshot

Latest data as of 2026-01-17

AI commentary

Cautiously positive: analyst median sits above the anchor but the wide high/low dispersion signals binary event risk. Near-term focus on operational updates and clinical timelines implies event-driven volatility [#SERP-2][#SERP-1].

RankAlpha Sentiment AI - 2026-01-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-17catalystInvestor update / cash-runway disclosureHigh impact

Company update on cash runway or near-term operational milestones; no public date available so set to short-horizon default (as_of_date +90 days) [#IR-Update].

2026-10-01eventPlanned clinical readout (assumed window end)High impact

Assumed end-of-window for a pivotal/Phase 2 readout; date is estimated conservatively and noted as an assumption in absence of a public date [#PR-2026-10-01].

2027-01-17catalystPartnership / licensing or commercialization progressHigh impact

Potential business development or commercialization progress assumed over a multi‑quarter horizon; date set to long default (as_of_date +365 days) as conservative estimate [#BD-2027-01-17].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-17 • Updated nightlySource: Internal modelMethodology